Dihydrofolate Reductase Assay Kit (Colorimetric) (ab239705)
Key features and details
- Detection method: Colorimetric
- Platform: Microplate reader
- Sample type: Adherent cells, Suspension cells, Tissue
Overview
-
Product name
Dihydrofolate Reductase Assay Kit (Colorimetric)
See all Dihydrofolate reductase (DHFR) kits -
Detection method
Colorimetric -
Sample type
Tissue, Adherent cells, Suspension cells -
Product overview
Dihydrofolate Reductase Assay Kit (Colorimetric) (ab239705) is based on the ability of DHFR to catalyze the oxidation of NADPH. The reaction progress is followed by monitoring the decrease in absorbance at 340 nm. Our assay has been optimized to be carried out in a 96-well plate. It is simple, sensitive and can detect as low as 4 mU/ml in a variety of samples.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called K246 Dihydrofolate Reductase Activity Kit (Colorimetric). K246-100 is the same size as the 100 test size of ab239705.
-
Platform
Microplate reader
Properties
-
Storage instructions
Please refer to protocols. -
Components 100 tests DHFR Assay Buffer 1 x 35ml DHFR Substrate 1 x 450µl Dihydrofolate Reductase 1 x 10µl NADPH III 1 vial -
Research areas
-
Function
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. -
Pathway
Cofactor biosynthesis; tetrahydrofolate biosynthesis; 5,6,7,8-tetrahydrofolate from 7,8-dihydrofolate: step 1/1. -
Sequence similarities
Belongs to the dihydrofolate reductase family.
Contains 1 DHFR (dihydrofolate reductase) domain. - Information by UniProt
-
Alternative names
- DHFR
- DHFRP1
- Dihydrofolate reductase
see all
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab239705 has been referenced in 1 publication.
- Barbieri F et al. Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives. J Exp Clin Cancer Res 41:53 (2022). PubMed: 35135603